Vitex / Chasteberry
Vitex agnus-castus
Evidence Rating
Confidence Level
Traditions
Last Updated
Summary
Vitex agnus-castus is the premier European phytomedicine for premenstrual syndrome (PMS), cyclical mastalgia, and menstrual irregularities. It holds "well-established use" status from the EMA/HMPC and a positive Commission E monograph. Its mechanism is uniquely well-characterized among gynecological herbs: diterpenes (clerodadienols) act as dopamine D2 receptor agonists, reducing prolactin secretion from the anterior pituitary. This explains its efficacy in conditions linked to latent hyperprolactinemia. The Ze 440 extract (Zeller, 20 mg/day) and BNO 1095 extract (Bionorica) are the best-studied preparations. Meta-analyses of 13-14 controlled trials consistently show benefit for PMS symptom reduction.
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | ✓ Approved |
| ESCOP (European) | ✓ Approved |
| EMA/HMPC (EU) | ✓ Approved |
Metadata
| Field | Detail |
|---|---|
| Common Names (English) | Chasteberry, Chaste Tree Berry, Vitex, Monk’s Pepper |
| Common Names (German) | Moenchspfeffer, Keuschlamm |
| Botanical Name | Vitex agnus-castus L. |
| Plant Family | Lamiaceae (formerly Verbenaceae) |
| Part Used | Ripe dried fruit (Agni casti fructus) |
| Evidence Quality Rating | Strong — Well-established use (EMA/HMPC), Commission E approved, multiple RCTs, well-characterized mechanism |
Approved Indications
Commission E (Germany, 1992)
- Menstrual cycle irregularities (anomalies of cycle length)
- Premenstrual complaints / disorders
- Mastodynia (breast pain)
ESCOP
- Premenstrual syndrome
- Menstrual cycle irregularities
- Cyclical mastalgia
EMA/HMPC
- Status: Well-Established Use
- Primary indication: Premenstrual syndrome (PMS)
- Assessment report: EMA/HMPC assessment on Vitex agnus-castus L., fructus (Revision 1)
Agreement/Disagreement Between Bodies
- Strong agreement: All three bodies list PMS and menstrual irregularities
- Commission E is broadest: Includes mastodynia as a standalone indication
- EMA is most specific: Focuses primarily on PMS as the well-established indication
- Mastalgia: Commission E and ESCOP list it; EMA includes it within the PMS symptom complex rather than as a separate indication
Conditions Treated
Primary (Evidence-Supported)
- Premenstrual syndrome (PMS): Strongest evidence — irritability, mood changes, headache, breast fullness, bloating
- Cyclical mastalgia / mastodynia: Strong evidence, linked to prolactin reduction
- Menstrual cycle irregularities: Oligomenorrhea, polymenorrhea
Secondary (Supported by Mechanism and Observational Data)
- Latent hyperprolactinemia: Direct pharmacological rationale
- Corpus luteum insufficiency: Improves progesterone levels in luteal phase via prolactin normalization
- Premenstrual dysphoric disorder (PMDD): Extension of PMS evidence [NEEDS-RESEARCH for specific PMDD trials]
- Subfertility related to luteal phase defects: Some evidence, discussed in systematic reviews
Investigated but Less Certain
- Fibrocystic mastopathy: Some positive data; overlaps with mastalgia indication
- Acne (hormonally driven): Limited evidence [UNCERTAIN]
Mechanism of Action
Primary Mechanism: Dopamine D2 Receptor Agonism
Vitex is unique among gynecological herbs in having a clearly elucidated, receptor-level mechanism of action.
Specific Compounds and Targets
| Compound Class | Key Compounds | Target | Effect |
|---|---|---|---|
| Diterpenes | Clerodadienols (rotundifuran, vitexilactone) | Dopamine D2 receptors | Agonism -> prolactin suppression |
| Triterpenes | 3-epi-maslinic acid (most active) | Dopamine D2 receptors | Additional D2R agonism |
| Flavonoids | Casticin, penduletin | Opioid receptors (mu, kappa) | Possible analgesic effects |
| Iridoids | Agnuside, aucubin | Multiple | Anti-inflammatory, possibly hormonal modulation |
Mechanistic Cascade
- Diterpenes bind D2 receptors on anterior pituitary lactotroph cells
- Prolactin secretion is inhibited (demonstrated in vitro and in vivo)
- Reduced prolactin normalizes the hypothalamic-pituitary-gonadal axis
- Downstream effects:
- Normalization of FSH/LH ratio
- Improved corpus luteum function
- Increased luteal-phase progesterone
- Resolution of PMS symptoms linked to progesterone-prolactin imbalance
- Resolution of cyclical mastalgia (prolactin-driven)
Additional Activities
- Opioid receptor binding: Casticin and other flavonoids bind mu and kappa receptors (contributes to analgesic effects)
- Estrogen receptor beta modulation: Some compounds show weak ER-beta affinity [CONTESTED — significance unclear]
Clinical Evidence Summary
Pivotal Clinical Trials
Ze 440 Extract (Zeller AG, Switzerland)
| Study | Design | N | Duration | Key Finding |
|---|---|---|---|---|
| Schellenberg 2001 | RCT, DB, PC | 170 | 3 cycles | 52% improvement in PMS symptoms vs. 24% placebo; significant for irritability, mood, anger, headache, breast fullness |
| Schellenberg et al. 2012 | RCT, DB, PC, dose-finding | 162 | 3 cycles | 20 mg optimal dose; 8 mg insufficient; 30 mg no additional benefit over 20 mg |
BNO 1095 Extract (Bionorica)
| Study | Design | N | Duration | Key Finding |
|---|---|---|---|---|
| Multiple controlled trials | Various | Various | 3+ cycles | Reduction in irregular cycle (9.1% to 0.1%), breast tenderness (39.9% to 0.8%) |
Meta-Analyses
| Review | Included Studies | Result |
|---|---|---|
| Verkaik et al. 2017 (AJOG) | 14 controlled studies | 13 of 14 reported positive effects on PMS symptoms |
| Csupor et al. 2019 | DB-RCTs only | Statistically significant benefit for PMS; pooled effect favoring VAC |
Mastalgia-Specific Evidence
- Systematic review and meta-analysis (2019) found Vitex effective for cyclic mastalgia
- Clear correlation between prolactin reduction and breast pain improvement in placebo-controlled studies
- Several studies show VAC extracts effective in fibrocystic mastopathy
European vs. US/Anglophone Consensus
| Aspect | European Consensus | US/Anglophone Consensus |
|---|---|---|
| Regulatory status | Well-established use (EMA); approved (Commission E) | Dietary supplement (FDA); no formal approval |
| PMS treatment | Accepted first-line phytotherapy option | Acknowledged as potentially useful; ACOG does not include in guidelines |
| Mechanism | Dopaminergic mechanism well-accepted | Less widely known among clinicians |
| Product specificity | Specific extracts (Ze 440, BNO 1095) with documented dosing | Generic products of varying quality dominant |
| Mastalgia | Recognized indication (Commission E) | Not widely used for this indication |
| Integration | Part of mainstream gynecological practice in Germany | Primarily used in integrative/naturopathic medicine |
Safety Profile
Contraindications
- Known hypersensitivity to Vitex agnus-castus or Lamiaceae
- Pregnancy: Contraindicated — may affect hormonal balance; animal data suggests possible effects on pregnancy outcomes
- Lactation: Contraindicated — may suppress prolactin and therefore milk production
- Hormone-sensitive conditions: Caution in estrogen-dependent tumors (theoretical, based on weak ER-beta activity)
- Children and adolescents: Not recommended (insufficient data)
Drug Interactions
- Dopamine antagonists (antipsychotics, metoclopramide, domperidone): Theoretical pharmacological antagonism — Vitex’s dopaminergic action could counteract these drugs
- Oral contraceptives: Theoretical interference with hormonal contraception via effects on FSH/LH; clinical significance uncertain but patients should be informed
- Hormone replacement therapy: May interact; avoid concurrent use without medical supervision
- Dopamine agonists (bromocriptine, cabergoline): Additive effect; combination not recommended without supervision
- No known CYP450 interactions of clinical significance reported
Side Effects
- Mild and reversible in clinical trials:
- Nausea
- Headache
- Gastrointestinal disturbances
- Menstrual flow changes (temporary)
- Acne (rare)
- Pruritus and erythematous rash (rare)
- Dizziness (rare)
- Adverse events reported in systematic review were generally mild
Pregnancy and Lactation
- Pregnancy: Contraindicated. Animal studies suggest possible effects on pregnancy rate, live birth rate, abortion, and stillbirth rates. Should be discontinued upon confirmed pregnancy.
- Lactation: Contraindicated due to anti-prolactin effects potentially reducing milk supply.
- Fertility context: Used by some practitioners to support conception in luteal phase deficiency, but should be discontinued once pregnancy is confirmed. This use requires medical supervision.
Clinical Dosage
Recommended Forms and Doses
| Form | Preparation | Daily Dose | Notes |
|---|---|---|---|
| Ze 440 extract | 60% ethanol (m/m), DER 6-12:1 | 20 mg/day (one tablet) | Optimal dose established by dose-finding study |
| BNO 1095 extract | Aqueous/ethanolic extract | 4-40 mg/day | Used in multiple clinical trials |
| Dried fruit | Powdered | 20-240 mg/day | Less standardized |
| Tincture (1:5) | Ethanolic | 0.5-1.0 mL/day | Traditional form |
| Fluid extract | Various | 0.5-1.0 mL/day | Various ratios |
Key Products
| Product | Manufacturer | Country | Extract | Daily Dose |
|---|---|---|---|---|
| Premular/Prefemin | Zeller AG | Switzerland | Ze 440 | 20 mg |
| Agnolyt | Bionorica | Germany | BNO 1095 | 3.2-4.8 mg dry extract |
| Femicur | Various | Germany | Various | Product-specific |
| Vitex | Various | International | Non-standardized | Varies widely |
Duration and Onset
- Onset of effect: Typically 1-3 menstrual cycles (4-12 weeks)
- Recommended duration: At least 3 consecutive menstrual cycles
- Long-term use: Generally safe for up to 6-18 months; reassess periodically
- Timing: Take in the morning (aligns with circadian prolactin regulation)
Connections
- Compare with Black Cohosh — different mechanism (dopaminergic vs. serotonergic/GABAergic) and different primary indications (PMS vs. menopause)
- The prolactin-lowering mechanism is relevant to understanding mastalgia treatment; see also Evening Primrose Oil which is used for the same indication with a different rationale
- For menstrual irregularities, compare with Dong Quai — much weaker evidence base for the same claimed indications
Related Herbs
Black Cohosh
Actaea racemosa / Cimicifuga racemosa
Black Cohosh is the best-studied herbal medicine for menopausal vasomotor symptoms in the European phytotherapy tradition. It holds "well-established use" status from the EMA/HMPC, a positive Commission E monograph, and an ESCOP monograph. The primary commercial product, Remifemin (isopropanolic extract, 40 mg/day), has demonstrated efficacy comparable to low-dose conjugated estrogens in some trials. The mechanism is non-estrogenic, acting through serotonergic, dopaminergic, and GABAergic pathways. The hepatotoxicity debate, which generated significant regulatory concern in the mid-2000s, has been largely resolved: rigorous causality assessments found no probable causal link in the vast majority of reported cases, with product adulteration and confounding factors implicated instead.
Dong Quai
Angelica sinensis
Dong Quai (Angelica sinensis) is one of the most important herbs in Traditional Chinese Medicine (TCM) for women's health, earning the title "female ginseng." However, from the European evidence-based phytotherapy perspective, it represents the weakest herb in this collection. The EMA/HMPC explicitly REJECTED adoption of a monograph due to inadequate evidence of 30+ years of use in the EU, toxicological concerns, and the need for medical supervision. There is no Commission E monograph. The only major RCT as a standalone treatment (Hirata 1997, n=71) showed no benefit over placebo for menopausal symptoms. Significant safety concerns exist regarding anticoagulant interactions (documented potentiation of warfarin) and photosensitivity due to coumarin and furanocoumarin content. Dong Quai represents the largest gap between traditional reputation and evidence-based validation in this collection.
Evening Primrose Oil
Oenothera biennis
Evening Primrose Oil is one of the most widely used supplements for women's health, particularly for PMS and cyclical mastalgia. However, there is a notable gap between its consumer popularity and the strength of clinical evidence. The EMA/HMPC has granted only "traditional use" status, and only for dry skin conditions -- not for PMS or mastalgia. The active compound is gamma-linolenic acid (GLA), an omega-6 fatty acid precursor to anti-inflammatory prostaglandins. While some individual trials show positive results for mastalgia and PMS, systematic reviews and meta-analyses present mixed findings. The Cochrane review found insufficient evidence for atopic dermatitis. EPO represents a case where traditional reputation and consumer demand have outpaced scientific validation.